AUTHORS
Zongru Li, Yanli Zhang, MD2, Zhenfang Liu, DO3, Weiming Li, PhD4, Qiang WANG, MD5, Xin Du, MD6, Zhuogang Liu7, Xielan Zhao8, Jie Jin, MD9, Jianyu Weng, MD, PhD10, Bingcheng LIU, MD11, Jingrong Cao12, Hanying Bao, MD, PhD13, Qian Jiang Jr, MD14
AFFILIATIONS
1 Peking University Institute of Hematology, Beijing, China
2 Henan Cancer Hospital, Henan, China
3 The First Affiliated Hospital of Guangxi Medical University, Department of Hematology, Nanning, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Nanfang Hospital, Southern Medical University, Department of Hematology, Guangzhou, China
6 Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
7 Shengjing Hospital of China Medical University, Department of Hematology, Shenyang, China
8 Xiangya Hospital of Central South University, Changsha, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, Hangzhou, China
10 Guangdong Provincial People’s Hospital, Guangzhou, China
11 National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 Shenzhen TargetRx Inc., Shenzhen, China
13 Shenzhen TargetRx Inc., Shenzhen, China
14 Peking University Institute of Hematology, Beijing, China
ABSTRACT
Background
TGRX-678 is a novel allosteric inhibitor that selectively targets the STAMP domain of BCR::ABL1. Here, we report integrated safety and efficacy findings of the phase 1 TGRX-678-1001 study in subjects with newly diagnosed CML-CP.
Methods
The TGRX-678-1001 study is a phase 1 trial. All subjects received TGRX-678 80 mg orally once daily. Treatment-related adverse events (TRAEs) were evaluated according to CTCAE v5.0. Diagnosis of CML-CP and response assessments were performed according to the European Leukemia Net (ELN) 2013 recommendations. Efficacy endpoints included complete cytogenetic response (CCyR), major molecular response (MMR), and deeper molecular responses (MR4.0 and MR4.5). Data were analyzed as of the cutoff date of July 16, 2026.
Results
29 subjects with newly diagnosed CML-CP were enrolled (median age, 54 years (IQR, 21–72). 62% male. 18 subjects (62%) were at low risk, 10 (34%) at intermediate risk, and 1 (3%) at high risk. At data cutoff (July 16, 2026), 28 (90%) subjects remained on therapy. With a median follow up of 56 (IQR, 48–64) weeks, 28 (97%) subjects achieved CHR, CCyR and MMR. The responses increased over time. 69% (20/29) achieved MMR, 38% (11/29) achieved MR4.0, 28% (8/29) achieved MR4.5 at 48 weeks.1 subjects (3%) disease progression with no detectable ABL mutation.
Among the 29 safety-evaluable subjects, grade ≥3 TRAEs was limited to hematologic events including thrombocytopenia (21%),leukopenia (7%) , neutropenia (7%), and anemia (3%). The most common non-hematologic TRAEs (predominantly grade 1–2) were hypertriglyceridemia (31%), hypercholesterolemia (24%), hyperglycemia (21%). No grade 3–4 non-hematologic TRAEs were observed. TRAEs led to dose interruption in 8 subjects (28%), dose reduction in 3 subjects (10%), and no subjects experienced treatment discontinuation, and no deaths occurred.
Conclusions
TGRX-678 (80mg, QD) demonstrated robust cytogenetic and molecular responses in newly diagnosed CML-CP subjects with well tolerance. At week 48, MMR, MR4.0, and MR4.5 rates reached 69%, 38% and 28%, respectively. These findings support advancing TGRX-678 to frontline CML-CP.
DISCLOSURES
Zongru Li: No relevant conflicts of interest to declare.